Ineligibility required for 'anti-trials': inclusion in studies regardless of fitness

Vosaroxin for relapsed AML: Updates from VALOR

Impact of next-generation sequencing on treatment choice for MDS

Obinutuzumab extends PFS for follicular lymphoma in GALLIUM trial

Venetoclax plus cytarabine in elderly AML patients

Intravenous or subcutaenous rituximab for FL in the SABRINA study

Ibrutinib in CLL: RESONATE and resistance

Large granular lymphocyte proliferations in MDS

Durable remissions with the VcR-CVAD regimen for MCL regardless of age

TKI cessation for CML patients with deep molecular response: an update from the EURO-SKI trial

Tailoring therapy for leukaemia patients

Dose reduction of TKIs for CML patients with deep molecular response